Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Human Immunodeficiency Virus: full-pipeline trial registry
12 of 40 indexed Human Immunodeficiency Virus trials are currently recruiting.
Corpus placement: #368 of 28,707 conditions by registered trial count.
40 US clinical trials · 12 currently recruiting · #368 of 28,707 conditions by registered trial count
Human Immunodeficiency Virus: 40 US clinical trials tracked, 12 recruiting.
Human Immunodeficiency Virus is the subject of 40 registered US clinical trials on ClinicalTrials.gov, 12 of them currently open to new participants. 10 are in Phase 3-4 (later-stage) and 11 in Phase 1-2 (earlier-stage). The most active sponsor is University of California, San Francisco, running 4 of these trials.
Enrollment posture brief
Registry condition human-immunodeficiency-virus
OPEN 12 | RECR 30% | LATE 10 | EARLY 11 | RANK #368 | SPON 4
Volume-matched condition peers
Nearest open-share peer: Adrenocortical Carcinoma (30% recruiting · 10 trials)
Human Immunodeficiency Virus lists 12 open slots (30% of 40 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Human Immunodeficiency Virus on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Human Immunodeficiency Virus is recruiting below its size-band peers.
12 of 40 indexed trials (30%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Human Immunodeficiency Virus trials is spread across many organizations.
University of California, San Francisco accounts for 4 of 40 trials (10%). 29 distinct sponsors appear on at least one study for this condition label.
-
Typical Human Immunodeficiency Virus enrolment sits around 77 participants.
Median target enrolment is 77 among the 40 trials that report a genuine target (sentinel values excluded). 22 of those (55%) plan for fewer than 100 participants.
-
Human Immunodeficiency Virus research is mostly interventional.
32 interventional and 8 observational studies make up this index (80% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
40 total, page 1 of 1
Harm Reduction in HIV Primary Care for PLWH Who Use Drugs
University of Pittsburgh
NCT05404750
V+PSF-M for Tobacco Cessation in HIV Care in India
University of Colorado, Denver
NCT05786547
Cefixime Clinical Trial
University of Southern California
NCT04958122
Molecular Characterization of Viral-associated Tumors, Tumors Occurring in the Setting of HIV or Other Immune Disorders and Castleman Disease
National Cancer Institute (NCI)
NCT03300830
Text Education About Cardiovascular Health and HIV (TEACH-HIV)
University of California, San Francisco
NCT05642858
Immunogenicity of Gardasil-9 HPV Vaccine in People Living With HIV
Louisiana State University Health Sciences Center in New Orleans
NCT05266898
Cytotoxic T Lymphocytes in Treating Patients With Malignancies With BK and/or JC Virus
M.D. Anderson Cancer Center
NCT02479698
Baricitinib for Reduction of HIV - CNS
William Tyor
NCT05452564
Low Dose Naltrexone for Pain in Patients With HIV
Emory University
NCT05537935
Lenacapavir Intensification to Disrupt HIV Reservoirs in Virologically Suppressed People With HIV Receiving Antiretroviral Therapy
National Institute of Allergy and Infectious Diseases (NIAID)
NCT06819176
Tulane Abdominal Transplant Institute (TATI) of Solid Organ Transplantation of HIV-Positive Recipients From HIV-Positive Donors
Tulane University
NCT05159466
Gut Microbiota-Mediated Inflammatory Interactions Between AUD and HIV Infection
Rush University Medical Center
NCT06139224
Cross-disciplinary HIV Integrated Mental Health Support Intervention
Emory University
NCT04833829
Integration of Hypertension Management Into HIV Care in Nigeria
NYU Langone Health
NCT04704336
Increasing PrEP Use in High-Risk Social Networks of African-American MSM in Underserved Low-Risk Cities
Medical College of Wisconsin
NCT03823209
Health Information for Infected Veterans
VA Office of Research and Development
NCT03190317
Impact of HIV-1 and Aging on Mucosal Vaccine Responses
VA Eastern Colorado Health Care System
NCT03729778
3BNC117-LS and 10-1074-LS Plus N-803 (bNAb+N-803)
Rockefeller University
NCT05245292
Smoking Cessation for HIV/AIDS Patients
M.D. Anderson Cancer Center
NCT00502827
Improving Drug Adherence Among Adolescents in Uganda Using SMS Reminders
RAND
NCT02128087
HIV, Buprenorphine, and the Criminal Justice System (STRIDE2)
Yale University
NCT03583138
Body Image in Youth With HIV
St. Jude Children's Research Hospital
NCT01673750
The OPENS Trial: Offering Women PrEP (Aim 2)
University of California, San Francisco
NCT05619497
HIV Non-Occupational Post-Exposure Prophylaxis
Kenneth H. Mayer, MD
NCT01855867
First-in-human Study of 10-1074-LS Alone and in Combination With 3BNC117-LS
Rockefeller University
NCT03554408
Elite Controller and ART-treated HIV+ Statin Versus ASA Treatment Intervention Study
National Institute of Allergy and Infectious Diseases (NIAID)
NCT02081638
Buprenorphine and Integrated HIV Care
Yale University
NCT00317460
Biomarkers for Event-driven PrEP Adherence
Emory University
NCT04298697
Switching Undetectables to Selzentry
St. Hope Foundation
NCT01866267
CBSM Intervention Via mHealth to Ameliorate HIV-related Fatigue
Medical University of South Carolina
NCT03149094
Problems With Immune Recovery in the Gut Tissue
University of Minnesota
NCT01460433
Treatment of Acute Hepatitis C Virus in HIV Co-Infection
University of California, San Francisco
NCT00845676
Pharmacokinetic Interactions Between an Herbal Medicine (African Potato) and Antiretroviral Agents (Lopinavir/Ritonavir)
University of California, San Francisco
NCT01227590
Evaluation of the Safety of a Polyvalent Virus in Healthy Adults
St. Jude Children's Research Hospital
NCT00187044
The Happy Older Latinos Are Active (HOLA) Health Promotion Study in HIV-Infected Latino Men
University of Miami
NCT03839212
Post-Exposure Prophylaxis in Health Care Workers
Henry Ford Health System
NCT01234116
Trauma Intervention for Affect Regulation, AIDS, and Substances
University of Miami
NCT02923141
Relationship of Tenofovir With HIV-1 Suppression in ex Vivo Tissue in Adolescents
University of California, Los Angeles
NCT02134431
First in Human Study of TLC-ART 101 (ACTU 2001)
University of Washington
NCT05850728
Evaluating Drug Interactions Between Doravirine With Estradiol and Spironolactone in Healthy Transgender Women
Thomas Jefferson University
NCT04283656
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 8 |
| Phase 2 | 3 |
| Phase 3 | 2 |
| Phase 4 | 8 |
Top Sponsors
Named interventions
Most-linked intervention names on Human Immunodeficiency Virus records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Human Immunodeficiency Virus trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Human Immunodeficiency Virus page
40 registered trials, 12 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 12 Human Immunodeficiency Virus trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- University of California, San Francisco sponsors the most Human Immunodeficiency Virus trials on record, review their full trial history before evaluating a specific study. See University of California, San Francisco's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Human Immunodeficiency Virus condition card totals 40 registered trials; most-linked intervention 10-1074-LS; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.